Olaparib for the treatment of epithelial ovarian cancer

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

(2015) Christian Rolfo et al.   ADVANCES IN THERAPY

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

(2015) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

(2015) Haller J. Smith et al.   GYNECOLOGIC ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

(2011) T. Safra et al.   MOLECULAR CANCER THERAPEUTICS

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Making the best of PARP inhibitors in ovarian cancer

(2010) Susana Banerjee et al.   Nature Reviews Clinical Oncology

Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin

(2009) T. Hay et al.   CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

(2008) B. Evers et al.   CLINICAL CANCER RESEARCH

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

(2008) Keith A. Menear et al.   JOURNAL OF MEDICINAL CHEMISTRY

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA